Overview: TM6SF2 Genotype TestIntroduction: The TM6SF2 Genotype Test tests for TM6SF2 genotype to assess risk for fatty liver disease, helping guide dietary or medical interventions for liver health. Affecting 1 in 50 people with liver issues, TM6SF2 variants pose diagnostic challenges due to genetic complexity. Following 2023 American Association for the Study of Liver Diseases (AASLD) guidelines, it uses PCR/sequencing for high accuracy, supporting molecular pathology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in hepatology.
Other Names: TM6SF2 SNP Test, Fatty Liver Risk Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: TM6SF2 testing began in the 2010s with research by Kozlitina, who identified the variant. PCR/sequencing advancements by Illumina improved detection, surpassing earlier genotyping methods.
Purpose: Detects TM6SF2 genotype to assess fatty liver disease risk, guides dietary or medical interventions, and evaluates patients with liver issues, aiming to improve health.
Test Parameters: TM6SF2 genotype
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report history of liver issues.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document liver issues or obesity. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., cirrhosis), and sample collection risks.
Procedural Considerations: Uses PCR/sequencing to detect genotype, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Risk variant suggests fatty liver disease, guiding interventions. Early management might prevent progression, while untreated cases lead to cirrhosis. Normal genotype may require other tests.
Specialist Consultation: Consult a hepatologist for interpretation.
Additional Supporting Tests: Liver function tests, imaging, or biopsy to confirm diagnosis.
Test Limitations: Specific to TM6SF2; correlation with clinical status needed. False negatives possible with other variants.
References: AASLD Guidelines, 2023; Nature Genetics, Kozlitina J, 2022.
